Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Insmed's Brensocatib?
Brensocatib is a small molecule commercialized by Insmed, with a leading Phase III program in Bronchiectasis. According to Globaldata, it...
Brensocatib by Insmed for Hidradenitis Suppurativa: Likelihood of Approval
Brensocatib is under clinical development by Insmed and currently in Phase I for Hidradenitis Suppurativa. According to GlobalData, Phase I...
Brensocatib by Insmed for Cystic Fibrosis: Likelihood of Approval
Brensocatib is under clinical development by Insmed and currently in Phase II for Cystic Fibrosis. According to GlobalData, Phase II...
Brensocatib by Insmed for Rhinosinusitis: Likelihood of Approval
Brensocatib is under clinical development by Insmed and currently in Phase II for Rhinosinusitis. According to GlobalData, Phase II drugs...
Brensocatib by Insmed for Bronchiectasis: Likelihood of Approval
Brensocatib is under clinical development by Insmed and currently in Phase III for Bronchiectasis. According to GlobalData, Phase III drugs...